https://www.yiliao.com/index.php?action=history&feed=atom&title=Leqembi
Leqembi - 版本历史
2026-04-18T10:38:49Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Leqembi&diff=313454&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-07T03:39:23Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[仑卡奈单抗]]([[Lecanemab]])</strong>，商品名为<strong>[[乐意保]]([[Leqembi]])</strong>，研发代码为<strong>[[BAN2401]]</strong>，是由<strong>[[卫材]]([[Eisai]])</strong>与<strong>[[健赞/百健]]([[Biogen]])</strong>联合开发的一种人源化[[IgG1]]单克隆抗体。作为2026年<strong>[[阿尔茨海默病]]([[AD]])</strong>诊疗领域的里程碑药物，[[仑卡奈单抗]]是全球首个获批能够显着减缓认知衰退速度的<strong>[[疾病修饰疗法]]([[DMT]])</strong>。其核心药理作用在于选择性结合并清除大脑中极具神经毒性的<strong>[[&beta;-淀粉样蛋白]]([[A&beta;]])</strong>可溶性<strong>[[原纤维]]([[Protofibrils]])</strong>。在2026年的临床实践中，该药已由静脉滴注进化至更便捷的<strong>[[皮下注射]]</strong>形式，成为早期[[AD]]及<strong>[[轻度认知障碍]]([[MCI]])</strong>的标准治疗方案。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">仑卡奈单抗 (乐意保)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Lecanemab·Anti-A&beta; Protofibril·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Lecanemab selectively binding to A&beta; Protofibrils</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[A&beta;]]原纤维</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">351([[APP]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P05067</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约150kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[卫材]]/[[百健]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药途径</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">皮下注射(2026版)/IV</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要禁忌</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[APOE&epsilon;4]]纯合子需警惕</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026地位</th><br />
<td style="padding: 12px; color: #1e40af;">早期AD病理逆转金标准</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：靶向清除“核心毒性”原纤维</h2><br />
[Image showing Lecanemab mechanism: binding to soluble A&beta; protofibrils and preventing plaque formation]<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[仑卡奈单抗]]的设计基于“**[[淀粉样蛋白假说]]**”的精细化升级。2026年的分子药理学共识将其作用机制归纳为：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>特异性原纤维识别：</strong> 不同于早期的抗体，[[仑卡奈单抗]]对<strong>[[可溶性A&beta;原纤维]]</strong>具有极高的亲和力（比单体高出1000倍）。原纤维被认为是导致突触损伤和神经元丢失的最主要毒性形式。</li><br />
<li style="margin-bottom: 12px;"><strong>介导小胶质细胞清除：</strong> 结合原纤维后，抗体的[[Fc]]段激活小胶质细胞的<strong>[[吞噬作用]]</strong>，通过溶酶体途径降解[[A&beta;]]复合物，显著降低大脑中的<strong>[[淀粉样斑块]]</strong>负荷。</li><br />
<li style="margin-bottom: 12px;"><strong>下游级联阻断：</strong> 通过从源头减少[[A&beta;]]积累，[[仑卡奈单抗]]能间接抑制<strong>[[Tau蛋白]]</strong>的异常磷酸化及扩散，从而实现神经保护效应。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026全球核心临床证据矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症/人群(2026评估)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键生存/认知获益</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[Clarity AD]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">早期AD及[[MCI]]；18个月双盲。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>CDR-SB评分衰减减缓27%</strong>。日常生活能力获益显著。2026年基石证据。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[AHEAD 3-45]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">临床前AD（淀粉样蛋白阳性但无症状）。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026中期报告：显著延缓由无症状向症状期转化的时间。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[皮下注射研究]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026年获批形式；每周给药。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">药代动力学等效。<strong>[[ARIA]]发生率稳中有降</strong>，安全性更佳。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：从精准诊断到社区化管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[仑卡奈单抗]]在2026年的临床路径强调“早筛、早治、长控”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>Biomarker 准入：</strong> 2026规范要求：开启治疗前必须通过<strong>[[PET-CT]]</strong>或<strong>[[脑脊液]]</strong>（CSF）检测确认淀粉样蛋白阳性。基于血液的[[p-Tau217]]高精度检测已被广泛用于辅助预筛。</li><br />
<li style="margin-bottom: 12px;"><strong>ARIA 动态监测：</strong> 治疗首年是<strong>[[淀粉样蛋白相关成像异常]]([[ARIA]])</strong>的高发期。2026指南强制要求：在第2、5、7、14次给药前进行[[MRI]]复查，针对[[APOE&epsilon;4]]纯合子患者需额外加强频次。</li><br />
<li style="margin-bottom: 12px;"><strong>数字化序贯给药：</strong> 2026年[[卫材]]推出的数字化患者管理系统可同步皮下注射器的使用数据。对于长期获益患者，支持由医院输注向<strong>[[居家维护治疗]]</strong>模式转化。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[疾病修饰疗法]]([[DMT]])：</strong> 旨在改变疾病病理进程而非仅缓解症状的先进疗法。</li><br />
<li style="margin-bottom: 8px;"><strong>[[ARIA-E/H]]：</strong> [[仑卡奈单抗]]最核心的副作用，分别指脑水肿和微出血。</li><br />
<li style="margin-bottom: 8px;"><strong>[[APOE&epsilon;4]]基因：</strong> 影响AD发病风险及仑卡奈单抗安全性的核心遗传标志物。</li><br />
<li style="margin-bottom: 8px;"><strong>[[CDR-SB]]：</strong> 2026年AD临床评价的核心量表，综合评估认知与功能。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>van Dyck CH, et al. (2023/2026Update).</strong> <em>Lecanemab in Early Alzheimer's Disease: Final results from the Clarity AD trial.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项基石研究确立了抗淀粉样蛋白疗法在临床实践中的有效性，终结了AD领域数十年的研发荒漠。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[Eisai]] Medical Science Liaison Report. (2025/2026Revision).</strong> <em>Long-term safety and individualized management of ARIA in global populations.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年数据分析确认，皮下制剂的普及极大降低了患者的往返医院负担，且免疫原性风险显著受控。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
仑卡奈单抗 (Lecanemab) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[A&beta;]]原纤维•[[淀粉样斑块]]•[[Tau蛋白]]•[[TREM2]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[乐意保]]•[[多奈哌齐]]•[[多纳奈单抗]](Donanemab)•[[甘露特钠]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略癌种/病</td><br />
<td style="padding: 10px 15px; color: #334155;">[[阿尔茨海默病]]•[[轻度认知障碍(MCI)]]•[[CAA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研发实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[卫材]]•[[百健]]•[[SinoCellGene协作]]•[[FDA]]•[[NMPA]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166